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Serotonin (5-hydroxytryptamine or 5-HT) is an important neurotransmitter regulating a
wide range of physiological and pathological functions via activation of heterogeneously
expressed 5-HT receptors. The 5-HT7 receptor is one of the most recently described
members of the 5-HT receptor family. Functionally, 5-HT7 receptor is associated with
a number of physiological and pathological responses, including serotonin-induced
phase shifting of the circadian rhythm, control of memory as well as locomotor and
exploratory activity. A large body of evidence indicates involvement of the 5-HT7
receptor in anxiety and depression, and recent studies suggest that 5-HT7 receptor
can be highly relevant for the treatment of major depressive disorders. The 5-HT7
receptor is coupled to the stimulatory Gs-protein, and receptor stimulation results
in activation of adenylyl cyclase (AC) leading to a rise of cAMP concentration.
In addition, this receptor is coupled to the G12-protein to activate small GTPases
of the Rho family. This review focuses on molecular mechanisms responsible for
the 5-HT7 receptor-mediated signaling. We provide detailed overview of signaling
cascades controlled and regulated by the 5-HT7 receptor and discuss the functional
impact of 5-HT7 receptor for the regulation of different cellular and subcellular
processes.
Keywords: serotonergic signaling, G-protein coupled receptors, serotonin 5-HT7 receptor, heterotrimeric G-protein,
oligomerization, palmitoylation
GENERAL PRINCIPLES OF G-PROTEIN COUPLED RECEPTOR
SIGNALING
G-protein coupled receptors (GPCRs) represent the largest and
most diverse superfamily of transmembrane receptors divided
into five different families: rhodopsin, secretin, glutamate, adhe-
sion and frizzled receptors (Bjarnadóttir et al., 2006). Initial
studies with first discovered GPCRs, bovine rhodopsin and
β2 adrenergic receptor, arouse great interest in the field of
GPCRs, whose structures and functions became a subject of
extensive research (Nathans and Hogness, 1983; Dixon et al.,
1986). All these receptors function as signal-transducers by trans-
lating extracellular stimuli into intracellular responses result-
ing in multiple physiological as well as pathophysiological
responses (Thompson et al., 2008). All known GPCRs consist
of an extracellular amino-terminus, seven membrane-spanning
α-helices (for which reason they are often referred to as 7 trans-
membrane receptors), and an intracellular carboxyl-terminus.
Hence GPCR activity is induced by many different ligands,
the mechanism of sensing ligands and transducing signals are
highly variable (reviewed in Kristiansen, 2004). According to
the “allosteric ternary complex model”, GPCRs exist in equi-
librium between an inactive and active state (Christopoulos
and Kenakin, 2002), explaining the agonist-independent, con-
stitutive activity of some receptors (Seifert and Wenzel-Seifert,
2002).
HETEROTRIMERIC G-PROTEINS
Heterotrimeric G-proteins are the main downstream effectors of
GPCRs acting as molecular switches by turning on intracellular
downstream signaling cascades. They consist of three subunits,
α, β and γ and are divided into four subgroups according to
the structural and functional similarities of the Gα subunit. The
members of the stimulatory Gαs family stimulate adenylyl cyclases
(ACs), whereas inhibitory Gαi proteins inhibit ACs. The Gαq
class of G-proteins couples to phospholipase Cβ (PLCβ), while
Gα12 family members activate Rho guanine-nucleotide exchange
factors (Rho GEFs; Kristiansen, 2004). To date at least 16 different
genes encoding Gα subunits, 5 genes encoding Gβ subunits and
12 different genes encoding Gγ subunits have been discovered.
Although not all subunits do interact with each other, the diversity
of heterotrimeric G-proteins is still enormous, and this represents
an additional level of complexity by the regulation of multiple
signaling pathways (Cabrera-Vera et al., 2003).
Heterotrimeric G-proteins become activated by GPCRs via
complex conformational changes, which are also facilitated by
Gβγ dimers (Ford et al., 1998). Upon discovery of the het-
erotrimeric G-proteins, they were thought to conduct signals
exclusively via Gα-subunits. Later on, Gβγ dimer has also been
shown to directly modulate downstream effectors. First identi-
fied downstream target of Gβγ dimer was G-protein coupled
inward rectifier potassium (GIRK) channel (Logothetis et al.,
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1987). Nowadays, a list of downstream effectors regulated by
Gβγ dimers is permanently extending (Woehler and Ponimaskin,
2009).
In parallel with this classical G-protein mediated GPCR sig-
naling, non-classical (G-protein independent) signaling became
obvious during the last decade. This type of signaling will be also
discussed below.
G-PROTEIN INDEPENDENT SIGNALING
Beside the canonical GPCR signaling pathways via heterotrimeric
G-proteins, GPCRs can participate in non-canonical, G-protein
independent signaling. Main players of the G-protein indepen-
dent signaling are arrestins - a small family of cytosolic adaptor
proteins consisting of four members (Krupnick and Benovic,
1998). In contrast to arrestin 1 and arrestin 4 (X arrestin), which
are primary involved in adaption processes of opsins in rods
or cones, arrestin 2 and 3 (β-arrestin 1 and 2) are ubiquitously
expressed and can interact with different GPCRs (Lefkowitz and
Shenoy, 2005). Shortly after receptor stimulation, the C-terminal
tail of a GPCR often becomes substrate for the phosphoryla-
tion by G-protein coupled receptor kinases (GRKs; Gehret and
Hinkle, 2010). Phosphorylated receptors display a high affinity for
β-arrestin 1 and 2, which hinder interactions between receptor
and heterotrimeric G-protein resulting in desensitization and
damping of G-protein dependent signaling (Perry et al., 2002).
However, differently than thought at the beginning, arrestins
not only switch-off the GPCR-signaling, but can also lead to
the activation of alternative signaling pathways. Thus, β-arrestins
serve as a signaling hub, linking activated GPCRs to multiple
(G-protein independent) signaling pathways such as receptor
trafficking as well as in extending GPCR mediated signaling to
non-receptor tyrosine kinases (nRTKs) like proto-oncogene c-Src
(c-Src) and mitogen-activated protein kinases (MAPK) signaling
pathways.
5-HT7 RECEPTOR: PHYSIOLOGICAL FUNCTIONS AND
DISTRIBUTION IN THE BRAIN
The 5-HT7 receptor is one of the most recently discovered mem-
bers of the serotonin receptor family, which was cloned in 1993
independently by researchers in three laboratories (Bard et al.,
1993; Lovenberg et al., 1993; Ruat et al., 1993). The 5-HT7 recep-
tor gene is located on human chromosome 10q23.3-q24.3 with
an open reading frame containing 1335 base pairs and encoding a
protein of 445 amino acids (Bard et al., 1993). The 5-HT7 receptor
is broadly expressed in the central nervous system including
spinal cord (Dogrul and Seyrek, 2006), thalamus, hypothalamus,
hippocampus, prefrontal cortex, and the amygdala where it is
expressed in both neurons and glial cells (Hedlund and Sutcliffe,
2004; Thomas and Hagan, 2004; Russo et al., 2005). Significant
density of 5-HT7 receptor was observed in raphe nuclei area.
In contrast, receptor expression level detected in putamen and
cerebellum was relatively low (Horisawa et al., 2013). The 5-HT7
receptor is also expressed in the suprachiasmatic nucleus, and one
of the first functions proposed for the 5-HT7 receptor was the
regulation of sleep/wake cycles (Lovenberg et al., 1993). Func-
tional analysis demonstrated association of the 5-HT7 receptor
with central processes such as learning and memory, including
specific aspects of hippocampus-dependent information process-
ing (Hedlund and Sutcliffe, 2004; Ballaz et al., 2007; Eriksson
et al., 2008; Gasbarri et al., 2008; Hedlund, 2009). Moreover, 5-
HT7 receptor can be implicated in several neurological diseases
(Hedlund and Sutcliffe, 2004; Thomas and Hagan, 2004). It has
been shown that pharmacological blockade or knock-down of the
5-HT7 receptor induces antidepressant-like behavior in animal
models (Guscott et al., 2005; Hedlund et al., 2005; Wesołowska
et al., 2007). In addition, certain antidepressants may act directly
on the 5-HT7 receptor (Mullins et al., 1999), suggesting this recep-
tor as a novel target by the treatment of depression (Hedlund,
2009; Mnie-Filali et al., 2009). Analysis of mRNA expression level
revealed that the amount of 5-HT7 gene transcripts in the dorso-
lateral prefrontal cortex of schizophrenic patients was increased,
demonstrating that 5-HT7 receptor can also be associated with
schizophrenia (East et al., 2002; Pouzet et al., 2002; Ikeda et al.,
2006).
So far, three splice variants of the 5-HT7 receptor have been
identified in human, including 5-HT7(a), 5-HT7(b), 5-HT7(d),
three in mouse - 5-HT7(a), 5-HT7(b), 5-HT7(d), and four in rat -
5-HT7(a), 5-HT7(b), 5-HT7(c), 5-HT7(e) (Heidmann et al., 1997;
Liu et al., 2001). These splice variants differ only in their short
carboxyl-terminal amino acid sequence. Receptor isoforms have
altered patterns of tissue distribution, while no difference in their
pharmacological properties and coupling to ACs was observed
(Heidmann et al., 1997, 1998; Krobert et al., 2001). The human
5-HT7(d) receptor represents an exception, because this isoform
possesses a differential pattern of receptor internalization which
can affect receptor-mediated signaling (Guthrie et al., 2005).
In this regard, 5-HT7(d) receptor was constitutively internalized
in the absence of agonist suggesting that its carboxyl-terminal
tail, which is the longest among known human 5-HT7 recep-
tor isoforms, may contain a motif that interacts with cellular
transport machinery that is distinct from 5-HT7(a) and 5-HT7(b)
receptors.
GαS SIGNALING MEDIATED BY THE 5-HT7 RECEPTOR
The canonical signaling pathway of the 5-HT7 receptor is acti-
vation of Gs-protein which in turn can activate different AC
isoforms (Shen et al., 1993). ACs show a unique tissue distri-
bution as well as regulatory properties (Krupinski et al., 1989;
Bakalyar and Reed, 1990; Premont et al., 1996). In vitro, all
known AC isoforms are sensitive to the Gs activation (Cooper
et al., 1995; Taussig and Gilman, 1995; Sunahara et al., 1996).
In contrast, it has been demonstrated that Ca2+/calmodulin-
stimulated neural-specific isoforms AC1 and AC8 are insensitive
to Gs in vivo (Impey et al., 1994; Wayman et al., 1994; Nielsen
et al., 1996), and that 5-HT7(a) receptor isoform can stimulate
AC1 and AC8 by increasing intracellular Ca2+ concentration
(Baker et al., 1998). The coupling between 5-HT7 receptor and
Gs-protein results in increased AC activity leading to produc-
tion of cAMP, which in turn activates protein kinase A (PKA)
thereby inducing phosphorylation of different target proteins
(Figure 1). This results in activation of multiple downstream sig-
naling cascades, including Ras-dependent and Rap1-independent
activation of the neuroprotective extracellular signal-regulated
kinases (ERK) and Akt (protein kinase B) pathways (Errico et al.,
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FIGURE 1 | Schematic representation of signaling pathways regulated by
the 5-HT7 receptor. Effects mediated by Gs-proteins are in the left section.
Summary of the G12-mediated signaling processes is shown in the right
section. Abbreviations: GIRK—G-protein coupled inward rectifier potassium
channel; AC—adenylyl cyclase; cAMP—cyclic adenosine monophosphate;
PKA—protein kinase A; ERK—extracellular signal-regulated kinases;
Akt—protein kinase B, Hsp90—heat shot shock protein 90; ERM—proteins of
the ezrin-radixin-moesin family; GEF—guanine-nucleotide exchange factor
(represented by the leukemia-associated RhoGEF LARG and p115Rho);
nRTKs—non-receptor tyrosine kinases; AKAPs—A-kinase anchoring proteins;
ZO—zona occludens proteins; SRF—serum response factor; SRE—serum
response element.
2001; Johnson-Farley et al., 2005). Noteworthy, 5-HT7 receptor-
mediated activation of Akt requires increases both in [cAMP]
and intracellular [Ca2+], while activation of ERK is inhibited
by Ca2+ (Figure 1). However, neither an influx of extracellular
Ca2+ nor release of intracellular Ca2+ stores was required for 5-
HT7 receptor-mediated activation of ERK in cultured primary
hippocampal neurons (Lin et al., 2003). The authors of this study
also demonstrated that increase in cAMP concentration causes
activation of ERK in neurons via a pathway independent of PKA
and Raf-1 (Li et al., 1991; Kyriakis et al., 1992). It is widely
accepted, that intracellular pathways regulating ERK1/2 and Akt
signaling are involved in actin filament reorganization. On the
other hand, studies with LM2 cells, which are able to invade
into the lung tissue in vivo, revealed no significant inhibition
in cell motility after Ras-ERK pathway blockade, while PI3K
pathways was critically involved in regulation of motility of LM2
cells (Choi and Helfman, 2014). It has been also shown that
activation of PI3K activity alone is sufficient to remodel actin
filaments and to increase cell migration through the activation of
Akt in chicken embryo fibroblast (Qian et al., 2004). Thus, 5-HT7
receptor-mediated activation of Gs-protein can be involved in the
activation of effector molecules regulating the cellular motility
and cytoskeleton formation.
Gα12 SIGNALING MEDIATED BY THE 5-HT7 RECEPTOR
In our previous studies we have demonstrated that 5-HT7 recep-
tor is coupled not only to the Gs-protein, but can also activate
G12-protein (Figure 1; Kvachnina et al., 2005; Kobe et al., 2012).
The G12-proteins have been shown to activate multiple
signaling pathways, and their prominent downstream effec-
tors are members of the Rho family of small GTPases (Rho,
Rac, and Cdc42). The G12-protein can modulate the activity
of Rho GTPases by activation of guanine-nucleotide exchange
factor (GEF) p115Rho which was the first identified down-
stream effector of Gα12 proteins (Hart et al., 1998; Kozasa
et al., 1998). Later on, plethora of additional downstream
targets of G12-proteins has been discovered. In addition to
other RhoGEFs, such as leukemia-associated RhoGEF (LARG)
and RhoGEF homologs in Caenorhabditis elegans, regula-
tor of G-protein signaling (RGS) family members, proteins
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of the ezrin-radixin-moesin (ERM) family, nRTKs, protein
phosphatases, A-kinase anchoring proteins (AKAPs), zona occlu-
dens proteins and heat shot shock protein 90 (Hsp90) have
been identified to directly interact with heterotrimeric G12-
protein (Figure 1; Hiley et al., 2006; Kelly et al., 2007).
The Gα12 subunit can also interact with C-terminal parts
of cadherins leading to release of β-catenin into cytoplasm
and nucleus, thus triggering gene transcription (Meigs et al.,
2001).
In case of 5-HT7 receptor, it has been reported that receptor-
mediated stimulation of G12-protein results in Rho-dependent
activation of a transcription factor, serum response factor (SRF),
which binds to the serum response element (SRE; Figure 1).
Noteworthy, stimulation of 5-HT7 receptor led to the dose-
dependent increase in SRE-driven gene expression even in the
presence of a PKA-inhibitor or pertussis toxin (PTX), suggesting a
receptor-mediated SRE activation in a PKA-independent manner
(Kvachnina et al., 2005). Recent findings also elucidated Rho-
independent mechanism of Gα12-mediated SRE activation via
Hsp90 (Figure 1; Montgomery et al., 2014). Interaction between
Gα12 and Hsp90 might also be critically involved in a selective
transport of the G12-protein to the lipid rafts (Waheed and Jones,
2002).
Detailed analysis of 5-HT7 receptor-mediated signaling
revealed that coupling of receptor to the heterotrimeric G12-
protein selectively activates both RhoA and Cdc42 (Kvachnina
et al., 2005), suggesting existence of cross-talk between Cdc42 and
RhoA pathways. This might be mediated via convergent actions of
these GTPases on the downstream effector myosin (Manser et al.,
1994; Amano et al., 1996). Alternatively, Cdc42 and RhoA may
function in a hierarchical cascade wherein Cdc42 downregulates
RhoA activity (Figure 1; Li et al., 2002).
In neuroblastoma cells, agonist-dependent activation of
recombinant 5-HT7 receptor induces pronounced filopodia for-
mation via a Cdc42-mediated pathway paralleled by the RhoA-
induced cell rounding (Kvachnina et al., 2005). Stimulation of the
5-HT7R/G12 signaling pathway in cultured hippocampal neurons
promotes formation of dendritic spines and accelerates synapto-
genesis, leading to enhanced spontaneous synaptic activity (Kobe
et al., 2012). Morphogenic action of 5-HT7 receptor was further
confirmed in experiments with striatal and cortical neuronal
cultures (Speranza et al., 2013). In this study authors observed
pronounced neurite outgrowth after specific activation of 5-HT7
receptor and demonstrated involvement of ERK and Cdk5 in this
process, presuming both proteins to be downstream signaling
molecules of Gα12 (Speranza et al., 2013).
Noteworthy that 5-HT7/G12 signaling in hippocampus
undergoes strong developmental regulation. In organotypic
hippocampal cultures from juvenile mice, 5-HT7R/G12 signaling
potentiates formation of dendritic spines, increases the basal neu-
ronal excitability and modulates synaptic plasticity. In contrast, in
older neuronal preparations, stimulation of 5-HT7 receptor had
no effect on neuronal morphology, synaptogenesis and synaptic
plasticity (Kobe et al., 2012). Accordingly, the expression level
of both 5-HT7 receptor and G12-protein in the hippocampus
is progressively decreased during postnatal development (Kobe
et al., 2012). Thus, 5-HT-induced activation of the 5-HT7R/G12
signaling pathways and the consequent reorganization of the
dendritic morphology appear to be a part of the molecular cas-
cade required for the growth of new synapses and the formation
of initial neuronal networks, which then become the subject of
activity-dependent structural and functional plasticity (Citri and
Malenka, 2008; Ibata et al., 2008).
HOMO- AND HETERODIMERIZATION OF 5-HT7 RECEPTORS
G-protein-coupled receptors were initially assumed to exist and
function as monomeric units that interact with corresponding G-
proteins in 1:1 stoichiometry. Recent studies revealed the capa-
bility of GPCRs to form oligomers (Devi, 2001; Bulenger et al.,
2005), and it is now widely accepted that homo- and heterodimer-
ization can represent an additional mechanism regulating GPCR-
mediated signaling.
Pharmacological analysis in combination with BRET
experiments demonstrated that 5-HT7 receptor can form
homooligomers in recombinant system (Teitler et al., 2010;
Figure 1). Existence of 5-HT7 receptor homodimers has also been
shown in primary cultures of rat cortical astrocytes (Smith et al.,
2011). Homooligomerization of 5-HT7 receptor at the single-cell
level has been further confirmed using two different FRET assays
(Renner et al., 2012).
By combined application of biochemical and biophysical
approaches we have recently demonstrated that 5-HT7 receptors
can form heterodimers with 5-HT1A receptors both in vitro and
in vivo (Renner et al., 2012; Figure 1). From the functional point
of view, heterodimerization decreases Gi-protein coupling of 5-
HT1A receptor and attenuates receptor-mediated activation of G-
protein-gated potassium (GIRK) channels, without substantial
changes in the coupling of 5-HT7 receptor to the Gs-protein.
Moreover, heterodimerization significantly facilitated internaliza-
tion of 5-HT1A receptor, while internalization kinetics of 5-HT7
receptor was decelerated upon heterodimerization (Renner et al.,
2012).
PALMITOYLATION OF THE 5-HT7 RECEPTOR
Many signaling molecules involved in GPCR-mediated signaling
are modified by post-translational modifications (Escribá et al.,
2007), such as phosphorylation, ubiquitination, glycosylation,
palmitoylation and others. The experiments with mutations of
two predicted N-glycosylation sites in 5-HT7(a) receptor (N5Q
and N66Q) revealed, that 5-HT7(a) receptor glycosylation neither
influence the binding of 5-CT agonist to the receptor, nor the
potency or efficacy with respect to activation of second messenger
cascades, although a decrease in receptor density is apparent for
the non-glycosylated receptor (Gellynck et al., 2012). To date,
no data about the phosphorylation or ubiquitination of 5-HT7
receptor are available.
Covalent attachment of long chain saturated fatty acids (i.e.,
palmitate) to cysteine residue(s) within the protein via a labile
thioester linkage (S-palmitoylation) represents a widespread post-
translational modification of GPCRs since approximately 80% of
all known receptors contain the potentially palmitoylable cysteine
residue(s) downstream of their seventh transmembrane domain
(Escribá et al., 2007). GPCR palmitoylation is involved in the
modulation of different receptor functions from coupling to
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FIGURE 2 | Hypothetical model for the regulation of 5-HT7 receptor
activity by dynamic palmitoylation. This model suggests existence of
two different receptor populations: Palmitoylated receptors with two
additional intracellular C-terminal loops (left) and non-palmitoylated
receptors with no intracellular C-terminal loops (right). These
populations exist in dynamic equilibrium regulated by basal or
agonist-promoted palmitate turnover. Depalmitoylation results in
significant increase of the receptor’s capacity to convert from the
inactive (R) to the active (R*) form in the absence of an agonists.
Palmitoylated receptor shows activation of both Gαs- and Gα12-proteins
(left). Non-palmitoylated receptor possesses increased
agonist-independent, constitutive activity (R*) towards Gαs-mediated
signaling, while basal receptor-mediated activation of Gα12-protein is
unaltered (right).
G-proteins and regulation of endocytosis to receptor phospho-
rylation and desensitization. Also the serotonin receptors repre-
sent potential substrates for palmitoylation, and palmitoylation
was experimentally demonstrated for 5-HT1A, 5-HT1B, 5-HT4
and 5-HT7 receptors (reviewed in Gorinski and Ponimaskin,
2013).
The mouse 5-HT7 receptor has been shown to undergo
dynamic palmitoylation in an agonist-dependent manner after
expression in Sf.9 insect cells. Mutation analysis demonstrated
that cysteines located in the C-terminal receptor domain at posi-
tions 404, 438 and 441 represent the main potential palmitoy-
lation sites (Figure 2). Although these cysteine residues were
responsible for the attachment of more than 90% of the receptor-
bound palmitate, palmitoylation of 5-HT7 receptor was still not
restricted to its C-terminus, pointing to the existence of additional
acylation site(s) within the receptor.
Functional analysis of palmitoylation-deficient mutants
revealed that agonist-induced activation of Gs- and G12-proteins
was unaffected. However, mutation of the Cys404 either alone or
in combination with Cys438/Cys441 significantly increased the
agonist-independent, Gs-mediated constitutive 5-HT7 receptor
activity, while the activation of G12-protein was not affected
(Figure 2; Kvachnina et al., 2009). Generally, these data suggest
that palmitoylation of 5-HT7 receptor might be directly involved
in the isomerization of the receptor from the inactive to the
active form in the absence of agonists. This transformation
can be realized by dictating the conformation of receptor’s
flexible cytoplasmic loops which might be involved either in
the receptor/Gs-protein recognition or in Gs-protein binding
and/or receptor-mediated Gs-protein activation (Figure 2).
In combination with the previous findings on the functional
role of 5-HT4 receptor palmitoylation (Ponimaskin et al.,
2002, 2005), this observation suggests that palmitoylation can
represent a general feature regulating constitutive receptor
activity. Moreover, in case of 5-HT7 receptor (which is coupled
to both, Gs- and G12-proteins) dynamic palmitoylation can
represent a molecular mechanism responsible for selective Gs- or
G12-mediated signaling.
PHARMACOLOGICAL PROPERTIES OF 5-HT7 RECEPTOR
During the last decade, several selective agonists and antago-
nists for 5-HT7 receptors have been developed and applied to
investigate its pharmacology. Pharmacological analysis revealed
that application of risperidone, 9-OH-risperidone, methiothepin,
bromocryptine, lisuride, and metergoline resulted in irreversible
inhibition of the recombinant 5-HT7 receptor expressed in
HEK-293 cells (Smith et al., 2006; Knight et al., 2009). In
contrast, action of other potent 5-HT7 receptor antagonists,
including clozapine, mesulergine, penfluridol, amperozide and
cinanserin is reversible and can be washed out (Knight et al.,
2009). In other study receptor-inactivating properties of risperi-
done, 9-OH-risperidone, bromocriptine, methiothepin, meter-
goline, and lisuride have been demonstrated. Noteworthy that
methiothepin and bromocriptine maximally inhibited forskolin-
stimulated adenylate cyclase, whereas the other drugs produced
partial inhibition, indicating the drugs are inducing slightly differ-
ent inactive conformations of the 5-HT7 receptor (Toohey et al.,
2009). Nowadays, the highly specific 5-HT7 receptor antagonist
SB-269970 (pK i = 8.9 nM) is a mostly used receptor antago-
nist for in vitro and in vivo studies (Kobe et al., 2012; Renner
et al., 2012; Tokarski et al., 2012; Vasefi et al., 2013; Guseva
et al., 2014; Monti and Jantos, 2014). For the pharmacological
activation of the receptor, a high-affinity receptor agonist 5-CT
(IC50 = 0.83 nM, EC50 13 nM) is widely used in a numerous
in vitro and in vivo studies (Guscott et al., 2003; Kobe et al.,
2012; Vasefi et al., 2013). However, 5-CT is known to activate
5-HT1A, 5-HT1B, and 5-HT1D receptors. Therefore, analysis of 5-
HT7 receptor functions by 5-CT requires parallel application of 5-
HT1A/1B/1D receptor antagonists. Recently, various novel selective
agonists such as AS-19, LP-44, LP-12, LP-211 and E-55888 were
developed in addition to 5-CT (reviewed in Di Pilato et al., 2014).
Amongst them two novel agonists, LP-211 and LP-378, have been
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investigated in regard to exploratory motivation, anxiety-related
profiles, and spontaneous circadian rhythm (Adriani et al., 2012).
The authors have shown that three- to four-fold dosage of LP-
378 was necessary to induce the same effect as LP-211. The latest
studies, both in vitro and in vivo, indicated LP-211 (K i = 379 nM)
as a more specific 5-HT7 receptor agonist with great potential
for future investigations (Speranza et al., 2013; Monti and Jantos,
2014).
ACKNOWLEDGMENTS
The work was supported by Deutsche Forschungsgemeinschaft
through the grant PO732 and Cluster of Excellence REBIRTH.
Authors thank ERA-NET Neuron EU program for support of the
project TargetECM.
REFERENCES
Adriani, W., Travaglini, D., Lacivita, E., Saso, L., Leopoldo, M., and Laviola, G.
(2012). Modulatory effects of two novel agonists for serotonin receptor 7 on
emotion, motivation and circadian rhythm profiles in mice. Neuropharmacology
62, 833–842. doi: 10.1016/j.neuropharm.2011.09.012
Amano, M., Ito, M., Kimura, K., Fukata, Y., Chihara, K., Nakano, T., et al. (1996).
Phosphorylation and activation of myosin by Rho-associated kinase (Rho-
kinase). J. Biol. Chem. 271, 20246–20249. doi: 10.1074/jbc.271.34.20246
Bakalyar, H. A., and Reed, R. R. (1990). Identification of a specialized adenylyl
cyclase that may mediate odorant detection. Science 250, 1403–1406. doi: 10.
1126/science.2255909
Baker, L. P., Nielsen, M. D., Impey, S., Metcalf, M. A., Poser, S. W., Chan, G., et al.
(1998). Stimulation of type 1 and type 8 Ca2+/calmodulin-sensitive adenylyl
cyclases by the Gs-coupled 5-hydroxytryptamine subtype 5-HT7A receptor. J.
Biol. Chem. 273, 17469–17476. doi: 10.1074/jbc.273.28.17469
Ballaz, S. J., Akil, H., and Watson, S. J. (2007). The 5-HT7 receptor: role in novel
object discrimination and relation to novelty-seeking behavior. Neuroscience
149, 192–202. doi: 10.1016/j.neuroscience.2007.07.043
Bard, J. A., Zgombick, J., Adham, N., Vaysse, P., Branchek, T. A., and Weinshank,
R. L. (1993). Cloning of a novel human serotonin receptor (5-HT7) positively
linked to adenylate cyclase. J. Biol. Chem. 268, 23422–23426.
Bjarnadóttir, T. K., Gloriam, D. E., Hellstrand, S. H., Kristiansson, H., Fredriksson,
R., and Schiöth, H. B. (2006). Comprehensive repertoire and phylogenetic
analysis of the G protein-coupled receptors in human and mouse. Genomics 88,
263–273. doi: 10.1016/j.ygeno.2006.04.001
Bulenger, S., Marullo, S., and Bouvier, M. (2005). Emerging role of homo- and
heterodimerization in G-protein-coupled receptor biosynthesis and maturation.
Trends Pharmacol. Sci. 26, 131–137. doi: 10.1016/j.tips.2005.01.004
Cabrera-Vera, T. M., Vanhauwe, J., Thomas, T. O., Medkova, M., Preininger, A.,
Mazzoni, M. R., et al. (2003). Insights into G protein structure, function and
regulation. Endocr. Rev. 24, 765–781. doi: 10.1210/er.2000-0026
Choi, C., and Helfman, D. M. (2014). The Ras-ERK pathway modulates cytoskele-
ton organization, cell motility and lung metastasis signature genes in MDA-MB-
231 LM2. Oncogene 33, 3668–3676. doi: 10.1038/onc.2013.341
Christopoulos, A., and Kenakin, T. (2002). G protein-coupled receptor allosterism
and complexing. Pharmacol. Rev. 54, 323–374. doi: 10.1124/pr.54.2.323
Citri, A., and Malenka, R. C. (2008). Synaptic plasticity: multiple forms, functions
and mechanisms. Neuropsychopharmacology 33, 18–41. doi: 10.1038/sj.npp.
1301559
Cooper, D. M., Mons, N., and Karpen, J. W. (1995). Adenylyl cyclases and the
interaction between calcium and cAMP signalling. Nature 374, 421–424. doi: 10.
1038/374421a0
Devi, L. A. (2001). Heterodimerization of G-protein-coupled receptors: pharma-
cology, signaling and trafficking. Trends Pharmacol. Sci. 22, 532–537. doi: 10.
1016/s0165-6147(00)01799-5
Di Pilato, P., Niso, M., Adriani, W., Romano, E., Travaglini, D., Berardi, F.,
et al. (2014). Selective agonists for serotonin 7 (5-HT7) receptor and their
applications in preclinical models: an overview. Rev. Neurosci. 25, 401–415.
doi: 10.1515/revneuro-2014-0009
Dixon, R. A., Kobilka, B. K., Strader, D. J., Benovic, J. L., Dohlman, H. G.,
Frielle, T., et al. (1986). Cloning of the gene and cDNA for mammalian
beta-adrenergic receptor and homology with rhodopsin. Nature 321, 75–79.
doi: 10.1038/321075a0
Dogrul, A., and Seyrek, M. (2006). Systemic morphine produce antinociception
mediated by spinal 5-HT7, but not 5-HT1A and 5-HT2 receptors in the spinal
cord. Br. J. Pharmacol. 149, 498–505. doi: 10.1038/sj.bjp.0706854
East, S. Z., Burnet, P. W., Kerwin, R. W., and Harrison, P. J. (2002). An RT-
PCR study of 5-HT(6) and 5-HT(7) receptor mRNAs in the hippocampal
formation and prefrontal cortex in schizophrenia. Schizophr. Res. 57, 15–26.
doi: 10.1016/s0920-9964(01)00323-1
Eriksson, T. M., Golkar, A., Ekström, J. C., Svenningsson, P., and Ogren, S. O.
(2008). 5-HT7 receptor stimulation by 8-OH-DPAT counteracts the impairing
effect of 5-HT(1A) receptor stimulation on contextual learning in mice. Eur. J.
Pharmacol. 596, 107–110. doi: 10.1016/j.ejphar.2008.08.026
Errico, M., Crozier, R. A., Plummer, M. R., and Cowen, D. S. (2001). 5-HT(7)
receptors activate the mitogen activated protein kinase extracellular signal
related kinase in cultured rat hippocampal neurons. Neuroscience 102, 361–367.
doi: 10.1016/s0306-4522(00)00460-7
Escribá, P. V., Wedegaertner, P. B., Goñi, F. M., and Vögler, O. (2007). Lipid-protein
interactions in GPCR-associated signaling. Biochim. Biophys. Acta 1768, 836–
852. doi: 10.1016/j.bbamem.2006.09.001
Ford, C. E., Skiba, N. P., Bae, H., Daaka, Y., Reuveny, E., Shekter, L. R., et al. (1998).
Molecular basis for interactions of G protein betagamma subunits with effectors.
Science 280, 1271–1274. doi: 10.1126/science.280.5367.1271
Gasbarri, A., Cifariello, A., Pompili, A., and Meneses, A. (2008). Effect of 5-HT(7)
antagonist SB-269970 in the modulation of working and reference memory in
the rat. Behav. Brain Res. 195, 164–170. doi: 10.1016/j.bbr.2007.12.020
Gehret, A. U., and Hinkle, P. M. (2010). Importance of regions outside the cytoplas-
mic tail of G-protein-coupled receptors for phosphorylation and dephosphory-
lation. Biochem. J. 428, 235–245. doi: 10.1042/bj20100139
Gellynck, E., Andressen, K. W., Lintermans, B., Haegeman, G., Levy, F. O.,
Vanhoenacker, P., et al. (2012). Biochemical and pharmacological study of N-
linked glycosylation of the human serotonin 5-HT7a receptor. FEBS J. 279,
1994–2003. doi: 10.1111/j.1742-4658.2012.08581.x
Gorinski, N., and Ponimaskin, E. (2013). Palmitoylation of serotonin receptors.
Biochem. Soc. Trans. 41, 89–94. doi: 10.1042/BST20120235
Guscott, M., Bristow, L. J., Hadingham, K., Rosahl, T. W., Beer, M. S., Stanton, J. A.,
et al. (2005). Genetic knockout and pharmacological blockade studies of the 5-
HT7 receptor suggest therapeutic potential in depression. Neuropharmacology
48, 492–502. doi: 10.1016/j.neuropharm.2004.11.015
Guscott, M. R., Egan, E., Cook, G. P., Stanton, J. A., Beer, M. S., Rosahl, T. W.,
et al. (2003). The hypothermic effect of 5-CT in mice is mediated through
the 5-HT7 receptor. Neuropharmacology 44, 1031–1037. doi: 10.1016/s0028-
3908(03)00117-5
Guseva, D., Holst, K., Kaune, B., Meier, M., Keubler, L., Glage, S., et al. (2014). Sero-
tonin 5-HT7 receptor is critically involved in acute and chronic inflammation of
the gastrointestinal tract. Inflamm. Bowel Dis. 20, 1516–1529. doi: 10.1097/MIB.
0000000000000150
Guthrie, C. R., Murray, A. T., Franklin, A. A., and Hamblin, M. W. (2005). Dif-
ferential agonist-mediated internalization of the human 5-hydroxytryptamine 7
receptor isoforms. J. Pharmacol. Exp. Ther. 313, 1003–1010. doi: 10.1124/jpet.
104.081919
Hart, M. J., Jiang, X., Kozasa, T., Roscoe, W., Singer, W. D., Gilman, A. G., et al.
(1998). Direct stimulation of the guanine nucleotide exchange activity of p115
RhoGEF by Galpha13. Science 280, 2112–2114. doi: 10.1126/science.280.5372.
2112
Hedlund, P. B. (2009). The 5-HT7 receptor and disorders of the nervous system:
an overview. Psychopharmacology (Berl) 206, 345–354. doi: 10.1007/s00213-009-
1626-0
Hedlund, P. B., Huitron-Resendiz, S., Henriksen, S. J., and Sutcliffe, J. G. (2005).
5-HT7 receptor inhibition and inactivation induce antidepressantlike behavior
and sleep pattern. Biol. Psychiatry 58, 831–837. doi: 10.1016/j.biopsych.2005.05.
012
Hedlund, P. B., and Sutcliffe, J. G. (2004). Functional, molecular and pharmacolog-
ical advances in 5-HT7 receptor research. Trends Pharmacol. Sci. 25, 481–486.
doi: 10.1016/j.tips.2004.07.002
Heidmann, D. E., Metcalf, M. A., Kohen, R., and Hamblin, M. W. (1997). Four 5-
hydroxytryptamine7 (5-HT7) receptor isoforms in human and rat produced by
alternative splicing: species differences due to altered intron-exon organization.
J. Neurochem. 68, 1372–1381. doi: 10.1046/j.1471-4159.1997.68041372.x
Frontiers in Behavioral Neuroscience www.frontiersin.org October 2014 | Volume 8 | Article 306 | 6
Guseva et al. 5-HT7 receptor-mediated signaling
Heidmann, D. E., Szot, P., Kohen, R., and Hamblin, M. W. (1998). Function
and distribution of three rat 5-hydroxytryptamine7 (5-HT7) receptor isoforms
produced by alternative splicing. Neuropharmacology 37, 1621–1632. doi: 10.
1016/s0028-3908(98)00070-7
Hiley, E., McMullan, R., and Nurrish, S. J. (2006). The Galpha12-RGS RhoGEF-
RhoA signalling pathway regulates neurotransmitter release in C. elegans.
EMBO J. 25, 5884–5895. doi: 10.1038/sj.emboj.7601458
Horisawa, T., Ishiyama, T., Ono, M., Ishibashi, T., and Taiji, M. (2013). Binding of
lurasidone, a novel antipsychotic, to rat 5-HT7 receptor: analysis by [3H]SB-
269970 autoradiography. Prog. Neuropsychopharmacol. Biol. Psychiatry 40, 132–
137. doi: 10.1016/j.pnpbp.2012.08.005
Ibata, K., Sun, Q., and Turrigiano, G. G. (2008). Rapid synaptic scaling induced by
changes in postsynaptic firing. Neuron 57, 819–826. doi: 10.1016/j.neuron.2008.
02.031
Ikeda, M., Iwata, N., Kitajima, T., Suzuki, T., Yamanouchi, Y., Kinoshita, Y.,
et al. (2006). Positive association of the serotonin 5-HT7 receptor gene with
schizophrenia in a Japanese population. Neuropsychopharmacology 31, 866–871.
doi: 10.1038/sj.npp.1300901
Impey, S., Wayman, G., Wu, Z., and Storm, D. R. (1994). Type I adenylyl cyclase
functions as a coincidence detector for control of cyclic AMP response element-
mediated transcription: synergistic regulation of transcription by Ca2+ and
isoproterenol. Mol. Cell. Biol. 14, 8272–8281.
Johnson-Farley, N. N., Kertesy, S. B., Dubyak, G. R., and Cowen, D. S. (2005).
Enhanced activation of Akt and extracellular-regulated kinase pathways by
simultaneous occupancy of Gq-coupled 5-HT2A receptors and Gs-coupled 5-
HT7A receptors in PC12 cells. J. Neurochem. 92, 72–82. doi: 10.1111/j.1471-
4159.2004.02832.x
Kelly, P., Casey, P. J., and Meigs, T. E. (2007). Biologic functions of the G12 subfam-
ily of heterotrimeric g proteins: growth, migration and metastasis. Biochemistry
46, 6677–6687. doi: 10.1021/bi700235f
Knight, J. A., Smith, C., Toohey, N., Klein, M. T., and Teitler, M. (2009). Phar-
macological analysis of the novel, rapid and potent inactivation of the human
5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone and other
inactivating antagonists. Mol. Pharmacol. 75, 374–380. doi: 10.1124/mol.108.
052084
Kobe, F., Guseva, D., Jensen, T. P., Wirth, A., Renner, U., Hess, D., et al. (2012).
5-HT7R/G12 signaling regulates neuronal morphology and function in an age-
dependent manner. J. Neurosci. 32, 2915–2930. doi: 10.1523/JNEUROSCI.2765-
11.2012
Kozasa, T., Jiang, X., Hart, M. J., Sternweis, P. M., Singer, W. D., Gilman, A. G., et al.
(1998). p115 RhoGEF, a GTPase activating protein for Galpha12 and Galpha13.
Science 280, 2109–2111. doi: 10.1126/science.280.5372.2109
Kristiansen, K. (2004). Molecular mechanisms of ligand binding, signal-
ing and regulation within the superfamily of G-protein-coupled recep-
tors: molecular modeling and mutagenesis approaches to receptor structure
and function. Pharmacol. Ther. 103, 21–80. doi: 10.1016/j.pharmthera.2004.
05.002
Krobert, K. A., Bach, T., Syversveen, T., Kvingedal, A. M., and Levy, F. O. (2001). The
cloned human 5-HT7 receptor splice variants: a comparative characterization
of their pharmacology, function and distribution. Naunyn Schmiedebergs Arch.
Pharmacol. 363, 620–632. doi: 10.1007/s002100000369
Krupnick, J. G., and Benovic, J. L. (1998). The role of receptor kinases and arrestins
in G protein-coupled receptor regulation. Annu. Rev. Pharmacol. Toxicol. 38,
289–319. doi: 10.1146/annurev.pharmtox.38.1.289
Krupinski, J., Coussen, F., Bakalyar, H. A., Tang, W. J., Feinstein, P. G., Orth, K., et al.
(1989). Adenylyl cyclase amino acid sequence: possible channel- or transporter-
like structure. Science 244, 1558–1564. doi: 10.1126/science.2472670
Kvachnina, E., Dumuis, A., Wlodarczyk, J., Renner, U., Cochet, M., Richter, D. W.,
et al. (2009). Constitutive Gs-mediated, but not G12-mediated, activity of the
5-hydroxytryptamine 5-HT7(a) receptor is modulated by the palmitoylation of
its C-terminal domain. Biochim. Biophys. Acta 1793, 1646–1655. doi: 10.1016/j.
bbamcr.2009.08.008
Kvachnina, E., Liu, G., Dityatev, A., Renner, U., Dumuis, A., Richter, D. W., et al.
(2005). 5-HT7 receptor is coupled to G alpha subunits of heterotrimeric G12-
protein to regulate gene transcription and neuronal morphology. J. Neurosci. 25,
7821–7830. doi: 10.1523/jneurosci.1790-05.2005
Kyriakis, J. M., App, H., Zhang, X. F., Banerjee, P., Brautigan, D. L., Rapp, U. R.,
et al. (1992). Raf-1 activates MAP kinase-kinase. Nature 358, 417–421. doi: 10.
1038/358417a0
Lefkowitz, R. J., and Shenoy, S. K. (2005). Transduction of receptor signals by beta-
arrestins. Science 308, 512–517. doi: 10.1126/science.1109237
Li, Z., Aizenman, C. D., and Cline, H. T. (2002). Regulation of rho GTPases by
crosstalk and neuronal activity in vivo. Neuron 33, 741–750. doi: 10.1016/s0896-
6273(02)00621-9
Li, P., Wood, K., Mamon, H., Haser, W., and Roberts, T. (1991). Raf-1: a kinase
currently without a cause but not lacking in effects. Cell 64, 479–482. doi: 10.
1016/0092-8674(91)90228-q
Lin, S. L., Johnson-Farley, N. N., Lubinsky, D. R., and Cowen, D. S. (2003).
Coupling of neuronal 5-HT7 receptors to activation of extracellular-regulated
kinase through a protein kinase A-independent pathway that can utilize Epac. J.
Neurochem. 87, 1076–1085. doi: 10.1046/j.1471-4159.2003.02076.x
Liu, H., Irving, H. R., and Coupar, I. M. (2001). Expression patterns of 5-HT7
receptor isoforms in the rat digestive tract. Life Sci. 69, 2467–2475. doi: 10.
1016/s0024-3205(01)01318-2
Logothetis, D. E., Kurachi, Y., Galper, J., Neer, E. J., and Clapham, D. E. (1987).
The beta gamma subunits of GTP-binding proteins activate the muscarinic K+
channel in heart. Nature 325, 321–326. doi: 10.1038/325321a0
Lovenberg, T. W., Baron, B. M., de Lecea, L., Miller, J. D., Prosser, R. A., Rea, M. A.,
et al. (1993). A novel adenylyl cyclase-activating serotonin receptor (5-HT7)
implicated in the regulation of mammalian circadian rhythms. Neuron 11, 449–
458. doi: 10.1016/0896-6273(93)90149-l
Manser, E., Leung, T., Salihuddin, H., Zhao, Z. S., and Lim, L. (1994). A brain
serine/threonine protein kinase activated by Cdc42 and Rac1. Nature 367, 40–
46. doi: 10.1038/367040a0
Meigs, T. E., Fields, T. A., McKee, D. D., and Casey, P. J. (2001). Interaction of
Galpha 12 and Galpha 13 with the cytoplasmic domain of cadherin provides
a mechanism for beta -catenin release. Proc. Natl. Acad. Sci. U S A 98, 519–524.
doi: 10.1073/pnas.021350998
Mnie-Filali, O., Lambas-Señas, L., Scarna, H., and Haddjeri, N. (2009). Therapeutic
potential of 5-HT7 receptors in mood disorders. Curr. Drug Targets 10, 1109–
1117. doi: 10.2174/138945009789735129
Montgomery, E. R., Temple, B. R., Peters, K. A., Tolbert, C. E., Booker, B. K.,
Martin, J. W., et al. (2014). Gα12 structural determinants of Hsp90 interaction
are necessary for serum response element-mediated transcriptional activation.
Mol. Pharmacol. 85, 586–597. doi: 10.1124/mol.113.088443
Monti, J. M., and Jantos, H. (2014). The role of serotonin 5-HT7 receptor in regu-
lating sleep and wakefulness. Rev. Neurosci. 25, 429–437. doi: 10.1515/revneuro-
2014-0016
Mullins, U. L., Gianutsos, G., and Eison, A. S. (1999). Effects of antidepressants on
5-HT7 receptor regulation in the rat hypothalamus. Neuropsychopharmacology
21, 352–367. doi: 10.1016/s0893-133x(99)00041-x
Nathans, J., and Hogness, D. S. (1983). Isolation, sequence analysis and intron-exon
arrangement of the gene encoding bovine rhodopsin. Cell 34, 807–814. doi: 10.
1016/0092-8674(83)90537-8
Nielsen, M. D., Chan, G. C., Poser, S. W., and Storm, D. R. (1996). Differential
regulation of type I and type VIII Ca2+-stimulated adenylyl cyclases by Gi-
coupled receptors in vivo. J. Biol. Chem. 271, 33308–33316. doi: 10.1074/jbc.
271.52.33308
Perry, S. J., Baillie, G. S., Kohout, T. A., McPhee, I., Magiera, M. M., Ang, K. L., et al.
(2002). Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by
beta-arrestins. Science 298, 834–836. doi: 10.1126/science.1074683
Ponimaskin, E., Dumuis, A., Gaven, F., Barthet, G., Heine, M., Glebov, K., et al.
(2005). Palmitoylation of the 5-hydroxytryptamine4a receptor regulates recep-
tor phosphorylation, desensitization and beta-arrestin-mediated endocytosis.
Mol. Pharmacol. 67, 1434–1443. doi: 10.1124/mol.104.008748
Ponimaskin, E. G., Profirovic, J., Vaiskunaite, R., Richter, D. W., and Voyno-
Yasenetskaya, T. A. (2002). 5-Hydroxytryptamine 4(a) receptor is coupled to the
Galpha subunit of heterotrimeric G13 protein. J. Biol. Chem. 277, 20812–20819.
doi: 10.1074/jbc.m112216200
Pouzet, B., Didriksen, M., and Arnt, J. (2002). Effects of the 5-HT(7) receptor
antagonist SB-258741 in animal models for schizophrenia. Pharmacol. Biochem.
Behav. 71, 655–665. doi: 10.1016/s0091-3057(01)00744-4
Premont, R. T., Matsuoka, I., Mattei, M. G., Pouille, Y., Defer, N., and Hanoune,
J. (1996). Identification and characterization of a widely expressed form of
adenylyl cyclase. J. Biol. Chem. 271, 13900–13907. doi: 10.1074/jbc.271.23.
13900
Qian, Y., Corum, L., Meng, Q., Blenis, J., Zheng, J. Z., Shi, X., et al. (2004). PI3K
induced actin filament remodeling through Akt and p70S6K1: implication of
Frontiers in Behavioral Neuroscience www.frontiersin.org October 2014 | Volume 8 | Article 306 | 7
Guseva et al. 5-HT7 receptor-mediated signaling
essential role in cell migration. Am. J. Physiol. Cell Physiol. 286, C153–C163.
doi: 10.1152/ajpcell.00142.2003
Renner, U., Zeug, A., Woehler, A., Niebert, M., Dityatev, A., Dityateva, G., et al.
(2012). Heterodimerization of serotonin receptors 5-HT1A and 5-HT7 differ-
entially regulates receptor signalling and trafficking. J. Cell Sci. 125, 2486–2499.
doi: 10.1242/jcs.101337
Ruat, M., Traiffort, E., Leurs, R., Tardivel-Lacombe, J., Diaz, J., Arrang, J. M., et al.
(1993). Molecular cloning, characterization and localization of a high-affinity
serotonin receptor (5-HT7) activating cAMP formation. Proc. Natl. Acad. Sci.
U S A 90, 8547–8551. doi: 10.1073/pnas.90.18.8547
Russo, A., Pellitteri, R., Monaco, S., Romeo, R., and Stanzani, S. (2005). “In
vitro” postnatal expression of 5-HT7 receptors in the rat hypothalamus: an
immunohistochemical analysis. Brain Res. Dev. Brain Res. 154, 211–216. doi: 10.
1016/j.devbrainres.2004.11.002
Seifert, R., and Wenzel-Seifert, K. (2002). Constitutive activity of G-protein-
coupled receptors: cause of disease and common property of wild-type
receptors. Naunyn Schmiedebergs Arch. Pharmacol. 366, 381–416. doi: 10.
1007/s00210-002-0588-0
Shen, Y., Monsma, F. J. Jr., Metcalf, M. A., Jose, P. A., Hamblin, M. W., and Sibley,
D. R. (1993). Molecular cloning and expression of a 5-hydroxytryptamine7
serotonin receptor subtype. J. Biol. Chem. 268, 18200–18204.
Smith, C., Rahman, T., Toohey, N., Mazurkiewicz, J., Herrick-Davis, K., and
Teitler, M. (2006). Risperidone irreversibly binds to and inactivates the h5-
HT7 serotonin receptor. Mol. Pharmacol. 70, 1264–1270. doi: 10.1124/mol.106.
024612
Smith, C., Toohey, N., Knight, J. A., Klein, M. T., and Teitler, M. (2011).
Risperidone-induced inactivation and clozapine-induced reactivation of rat cor-
tical astrocyte 5-hydroxytryptamine7 receptors: evidence for in situ G protein-
coupled receptor homodimer protomer cross-talk. Mol. Pharmacol. 79, 318–325.
doi: 10.1124/mol.110.069278
Speranza, L., Chambery, A., Di Domenico, M., Crispino, M., Severino, V.,
Volpicelli, F., et al. (2013). The serotonin receptor 7 promotes neurite outgrowth
via ERK and Cdk5 signaling pathways. Neuropharmacology 67, 155–167. doi: 10.
1016/j.neuropharm.2012.10.026
Sunahara, R. K., Dessauer, C. W., and Gilman, A. G. (1996). Complexity and
diversity of mammalian adenylyl cyclases. Annu. Rev. Pharmacol. Toxicol. 36,
461–480. doi: 10.1146/annurev.pharmtox.36.1.461
Taussig, R., and Gilman, A. G. (1995). Mammalian membrane-bound adenylyl
cyclases. J. Biol. Chem. 270, 1–4. doi: 10.1074/jbc.270.1.1
Teitler, M., Toohey, N., Knight, J. A., Klein, M. T., and Smith, C. (2010). Clozapine
and other competitive antagonists reactivate risperidone-inactivated h5-HT7
receptors: radioligand binding and functional evidence for GPCR homod-
imer protomer interactions. Psychopharmacology (Berl) 212, 687–697. doi: 10.
1007/s00213-010-2001-x
Thomas, D. R., and Hagan, J. J. (2004). 5-HT7 receptors. Curr. Drug Targets CNS
Neurol. Disord. 3, 81–90. doi: 10.2174/1568007043482633
Thompson, M. D., Cole, D. E., and Jose, P. A. (2008). Pharmacogenomics of G
protein-coupled receptor signaling: insights from health and disease. Methods
Mol. Biol. 448, 77–107. doi: 10.1007/978-1-59745-205-2_6
Tokarski, K., Zelek-Molik, A., Duszyn´ska, B., Satała, G., Bobula, B., Kusek, M.,
et al. (2012). Acute and repeated treatment with the 5-HT7 receptor antag-
onist SB 269970 induces functional desensitization of 5-HT7 receptors in
rat hippocampus. Pharmacol. Rep. 64, 256–265. doi: 10.1016/s1734-1140(12)
70763-6
Toohey, N., Klein, M. T., Knight, J., Smith, C., and Teitler, M. (2009). Human
5-HT7 receptor-induced inactivation of forskolin-stimulated adenylate cyclase
by risperidone, 9-OH-risperidone and other “inactivating antagonists”. Mol.
Pharmacol. 76, 552–559. doi: 10.1124/mol.109.056283
Vasefi, M. S., Yang, K., Li, J., Kruk, J. S., Heikkila, J. J., Jackson, M. F., et al.
(2013). Acute 5-HT7 receptor activation increases NMDA-evoked currents and
differentially alters NMDA receptor subunit phosphorylation and trafficking in
hippocampal neurons. Mol. Brain 6:24. doi: 10.1186/1756-6606-6-24
Waheed, A. A., and Jones, T. L. (2002). Hsp90 interactions and acylation target the
G protein Galpha 12 but not Galpha 13 to lipid rafts. J. Biol. Chem. 277, 32409–
32412. doi: 10.1074/jbc.c200383200
Wayman, G. A., Impey, S., Wu, Z., Kindsvogel, W., Prichard, L., and Storm, D. R.
(1994). Synergistic activation of the type I adenylyl cyclase by Ca2+ and Gs-
coupled receptors in vivo. J. Biol. Chem. 269, 25400–25405.
Wesołowska, A., Tatarczyn´ska, E., Nikiforuk, A., and Chojnacka-Wójcik, E. (2007).
Enhancement of the anti-immobility action of antidepressants by a selective 5-
HT7 receptor antagonist in the forced swimming test in mice. Eur. J. Pharmacol.
555, 43–47. doi: 10.1016/j.ejphar.2006.10.001
Woehler, A., and Ponimaskin, E. G. (2009). G protein–mediated signaling:
same receptor, multiple effectors. Curr. Mol. Pharmacol. 2, 237–248. doi: 10.
2174/1874467210902030237
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 09 July 2014; paper pending published: 28 July 2014; accepted: 23 August
2014; published online: 01 October 2014.
Citation: Guseva D, Wirth A and Ponimaskin E (2014) Cellular mecha-
nisms of the 5-HT7 receptor-mediated signaling. Front. Behav. Neurosci. 8:306.
doi: 10.3389/fnbeh.2014.00306
This article was submitted to the journal Frontiers in Behavioral Neuroscience.
Copyright © 2014 Guseva, Wirth and Ponimaskin. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Behavioral Neuroscience www.frontiersin.org October 2014 | Volume 8 | Article 306 | 8
